Western Oncolytics is a biotech company developing novel virus-based cancer therapy, which delivers genes to guide the immune system to kill cancer cells. Western Oncolytics licensed novel WO-12 cancer therapy from University of Pittsburgh developed by Prof. Stephen Thorne, that use genetically engineered viruses to attack only cancer cells of solid tumor types while also delivering therapeutic genes.
Western Oncolytics Ltd.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/western-oncolytics-ltd-” connections=”true” suffix=””]
In July 2016, Pfizer and Western Oncolytics signed a collaboration on preclinical and clinical development of WO-12 through Phase I trials. Following completion of Phase I trials, Pfizer has an exclusive option to acquire WO-12. Financial terms of the agreement were not disclosed.
In June 2014, Western Oncolytics secured $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy.